SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple's XRP is trending as the community speculates on the potential passage of the Clarity Act and monitors upcoming institutional milestones like the DTCC's commercial launch. While some investors view recent price fluctuations as a setup for a major breakout driven by utility and regulatory progress, others remain skeptical, engaging in heated debates over market manipulation and the long-term viability of the asset.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is gaining significant momentum as investors digest positive Phase 3 clinical results for its COMP360 psilocybin therapy, fueling a wave of analyst upgrades and heightened institutional interest ahead of a planned NDA submission. The community is actively discussing the potential for rapid commercial adoption in treatment-resistant depression, with many traders holding for long-term FDA approval while focusing on the stock's relative strength and favorable cash position compared to sector peers.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is currently trending as a prominent AI infrastructure play, with investors closely watching its potential breakout toward key psychological resistance levels. The community remains highly focused on the company's role in the AI data center buildout, with frequent debates centering on whether current valuation and networking demand can sustain its long-term growth trajectory.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing intense volatility and heavy trading volume as investors react to the imminent closing of the TopBuild acquisition and resulting share conversions. Community members are actively debating the impact of the merger's dilution and deal structure, with bullish long-term holders focused on the company's potential as an integrated industrial leader while others express frustration over recent price action.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is experiencing significant momentum driven by its exclusive role in TSMC's COUPE silicon photonics ecosystem and increasing integration into next-generation AI and automotive display projects. The community is actively discussing the company's potential as a critical AI infrastructure enabler, while technical traders are closely monitoring price action following a strong breakout and recent shift in institutional sentiment.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is currently trending as investors monitor recent institutional accumulation and insider buying following a capital raise, while the community remains fixated on upcoming clinical readouts in epilepsy and oncology as the primary catalysts for a turnaround. Traders are heavily focused on navigating regulatory risks after past FDA setbacks and are speculating on the timing of further data releases across the company's multi-platform pipeline.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

The Vanguard Total Stock Market ETF is currently trending as investors debate the merits of passive, broad-market index strategies against the backdrop of heightened volatility and individual stock rotation. Community discourse remains centered on the efficacy of long-term 'set-and-forget' indexing versus active trading, especially as retail participants weigh new policy proposals for newborn investment accounts against broader macroeconomic concerns.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The IWM is currently in focus as investors analyze its resilience and role in sector rotation, while community sentiment remains divided between those capitalizing on short-term price action and those concerned about macro risks and potential market overextension. Active discussions center on the index's structural resistance levels, the impact of interest rate expectations on small-cap performance, and whether the recent price movement represents a genuine breakout or a temporary setup for a larger downside move.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions ($PENG) is drawing significant attention as traders bet on its role in the AI infrastructure buildout, fueled by recent earnings momentum and its status as an NVIDIA AI Factory partner. The community is heavily split between bulls who see a long-term growth story in AI-optimized memory and bears who remain cautious due to potential margin pressure, high short interest, and volatility leading up to upcoming earnings.

TOSHI

Toshi is trending as the community speculates on upcoming AI utility integrations and potential buyback mechanisms designed to reduce circulating supply. Investors are actively debating whether to accumulate during current consolidation levels while monitoring for technical breakouts and broader Base ecosystem momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of -50.00% and -46.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +3.73% and +5.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of +4.60% and +8.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells Biotechs Racing to...

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. PR...

Lineage Cell (LCTX) Reports Break-Even Earnings for Q4

Lineage Cell (LCTX) delivered earnings and revenue surprises of +100.00% and +187.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of +13.39% and -63.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Lags Q4 Earnings and Revenue Estimates

Pacira (PCRX) delivered earnings and revenue surprises of -32.74% and -0.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration PR Newswire VANCOUVER...

Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of -550.00% and +40.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Lineage Cell Therapeutics Inc

5 Stocks Retail Investors Are Most Bearish On At Mid-Day

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.02	--	--	N/A
Q1 '26	-$0.02	-$0.03	-50.00%	MISSED
Q4 '25	-$0.04	$0.00	109.33%	BEAT
Q3 '25	-$0.03	-$0.13	-405.56%	MISSED
Q2 '25	-$0.03	-$0.13	-387.49%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

LCTXLineage Cell Therapeutics Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest LCTX News